Phase II Results Show Rilzabrutinib Rapidly Reduces Severity of Itching Caused by Chronic Spontaneous Urticaria and Significantly Improves Disease Activity in Adults
Breaking data presented at the 2024 AAAAI Congress shows that rilzabrutinib, an oral BTK inhibitor, significantly reduces the ISS7 score (weekly pruritus intensity score), from the first week of treatment , in adults with moderate to severe UCS.
These data form the basis of phase III programs in the treatment of UCS and prurigo nodularis, which will begin in 2024.
Results from pivotal Phase III trials in the treatment of immune thrombocytopenia and Phase II trials in asthma, IgG4 disease and autoimmune hemolytic anemia are expected in 2024.
Rilzabrutinib is one of 12
blockbusters
potential of Sanofi’s cutting-edge immunology development portfolio.
Paris, February 24, 2024
. Positive results from the Phase II RILECSU study show that rilzabrutinib significantly relieves itching and urticaria in adults with moderate to severe chronic spontaneous urticaria (CSU), whose symptoms are inadequately controlled with antihistamines. H1. These results were presented today in the form of a poster at the 2024 Congress of the
American Academy of Allergy, Asthma and Immunology
(AAAAI) which is held in Washington, DC and forms the basis of the Phase III program which is expected to begin in 2024.
Dr. Marcus Maurer
Professor, Dermatology and Allergy, General Director of the Institute of Allergology, La Charité, Berlin
“People with CSU experience disabling symptoms, such as recurrent hive patches that cause intense itching or swelling, or both, which can have a significant impact on their daily lives. These data are promising for patients who cannot be controlled with conventional antihistamines – the ability to quickly control the itch with an oral medication would be an important advance in the treatment of this disease. »
Dr Naimish Patel
Global Head, Development, Immunology and Inflammation, Sanofi
“These data support the therapeutic potential of rilzabrutinib for patients with moderate to severe UCS. We believe that rapid improvement in pruritus could make an important difference and alleviate the physical and psychological burden on these patients. Armed with this data, we will move later this year to phase III of the development of this drug for the treatment of UCS, but also of prurigo nodularis, another skin disease characterized by incessant itching. This year, we also look forward to further results regarding rilzabrutinib, which may illustrate its potential impact on multiple immune diseases. »
Principle results
In this dose-finding study, different doses of rilzabrutinib were evaluated: 400 mg every evening, 400 mg twice a day, and 400 mg three times a day.
In the intention-to-treat (ITT) population, which included patients who had never been treated with omalizumab or had an incomplete response to this drug, rilzabrutinib 400 mg three times daily observed the following:
A significant reduction in the ISS7 score (severity score of pruritus, one of the main symptoms of the disease) at week 12, compared to the score at inclusion [moyenne des moindres carrés, respectivement -9,58 contre -6,31; p=0,0181]. Significant variations in the ISS7 score were observed from the first week of treatment.
A significant reduction in the UAS7 score (weekly urticaria activity score) at week 12, compared to the score at inclusion [moyenne des moindres carrés, respectivement -17,95 contre -11,20 ; p=0,0116].
A significant reduction in the HSS7 score (weekly urticaria severity score) at week 12, compared to the score at inclusion [moyenne des moindres carrés, respectivement -8,31 contre -4,89 ; p<0,0100].
Rilzabrutinib was generally well tolerated, with no cytopenia, bleeding, or episodes of atrial fibrillation, as is the case with other BTK inhibitors. The most frequently observed treatment-related adverse events in patients treated with rilzabrutinib, compared to placebo, were: diarrhea (29.3% 3 times daily and 2 times daily, 7.9% every evening, 15% placebo), nausea (19.5% 3 times a day, 17.1% 2 times a day, 13.2% every evening, 5.0% placebo), headache (9.8% 3 times per day, 14.6% 2 times daily, 5.3% every evening, 0.0% placebo) and abdominal pain (0.0% 3 times daily, 12.2% 2 times daily, 2, 6% every evening, 5.0% placebo).
Rilzabrutinib is currently undergoing clinical studies and no regulatory authority has yet evaluated its safety and efficacy profiles.
About chronic spontaneous urticaria
Chronic spontaneous urticaria (CSU) is an inflammatory skin disease resulting primarily from activation of cutaneous mast cells, which causes recurrent urticarial plaques and pruritus or edema, or both. UCS is usually treated with H1 antihistamines and biologic medications. However, almost 50% of patients remain uncontrolled and have access to only a limited number of other therapeutic options. They continue to experience symptoms that can be disabling and have significant negative effects on their quality of life.
About the RILECSU study
RILECSU is a 52-week Phase II study, comprising a 12-week randomized, double-blind, placebo-controlled period of dose finding and assessment of efficacy and safety, followed by ‘an open-label extension period of 40 weeks.
The RILECSU study is being conducted to evaluate rilzabrutinib in adults with moderate to severe UCS who remain symptomatic despite treatment with anti-H1 antihistamines and who have never been treated with omalizumab or have had an incomplete response. to this medicine. The primary endpoint was the change in ISS7 score (weekly pruritus severity score) at week 12, compared to the score at inclusion. Secondary endpoints included changes in weekly UAS7 AND HSS7 scores at week 12 from baseline.
Trial participants (n=160) were randomized 1:1:1:1 to receive rilzabrutinib 400 mg every night or 400 mg twice daily or 400 mg three times daily or one placebo.
About rilzabrutinib
Rilzabrutinib is an oral, reversible, covalent BTK inhibitor that has the potential to be first or best in class pharmacotherapeutics for the treatment of several autoimmune diseases. BTK, expressed in B cells and mast cells, plays an essential role in several autoimmune disease processes. Thanks to TAILORED COVALENCY technology
®
from Sanofi, rilzabrutinib can selectively inhibit the BTK target while potentially reducing the risk of off-target adverse effects.
About Sanofi
We are an innovative, global health company driven by a purpose: pursuing the miracles of science to improve people’s lives. Our teams, present in around a hundred countries, are working to transform the practice of medicine to make the impossible possible. We provide therapeutic solutions that can change the lives of patients and vaccines that protect millions of people around the world, guided by the ambition of sustainable development and our social responsibility.
Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY.
Media relations
Sandrine Guendoul
| + 33 6 25 09 14 25 |
Sally Bain
| +1 617 834 6026 |
Victor Rouault
| + 33 6 70 93 71 40 |
Investor relations
Eva Schaefer-Jansen
| + 33 7 86 80 56 39 | [email protected]
Arnaud Delépine
| + 33 6 73 69 36 93 | [email protected]
Corentine Driancourt
| + 33 6 40 56 92 21 | [email protected]
Felix Lauscher
| +1 908 612 7239 | [email protected]
Tarik Elgoutni|
+1 617 710 3587 | [email protected]
Nathalie Pham
| + 33 7 85 93 30 17 | [email protected]
Forward-looking statements
This release contains forward-looking statements. These statements do not constitute historical facts. These statements include projections and estimates and the assumptions on which they are based, statements regarding plans, objectives, intentions and expectations regarding financial results, events, operations, future services, product development and their potential or future performance. These forward-looking statements can often be identified by the words “expect”, “anticipate”, “believe”, “intend”, “estimate” or “plan” and other similar terms. Although Sanofi’s management believes that these forward-looking statements are reasonable, investors are cautioned that these forward-looking statements are subject to numerous risks and uncertainties, which are difficult to predict and generally beyond the control of Sanofi, which may imply that the actual results and events realized differ materially from those expressed, implied or anticipated in the forward-looking information and statements. These risks and uncertainties include in particular the uncertainties inherent in research and development, future clinical data and analyses, including post-marketing, decisions by regulatory authorities, such as the FDA or the EMA, to approve whether or not, and on what date, a drug, process or biological product filing application for one of these product candidates, as well as their labeling and other decisions factors that may affect the availability or commercial potential of these product candidates, the fact that the product candidates if approved may not achieve commercial success, the future approval and commercial success of therapeutic alternatives, the ability to Sanofi to seize external growth opportunities and finalize related transactions, the evolution of exchange rates and interest rates, the instability of economic and market conditions, cost control initiatives and their evolution, the impact that pandemics or any other global crisis could have on Sanofi, its customers, suppliers and partners and their financial situation, as well as on its employees and on the global economy. These risks and uncertainties also include those that are developed or identified in public documents filed by Sanofi with the AMF and the SEC, including those listed in the “Risk Factors” and “Forward-Looking Statements” sections of the Document. 2022 universal registration of Sanofi, which was filed with the AMF as well as in the sections “Risk Factors” and “Cautionary Statement Concerning Forward-Looking Statements” of the 2023 annual report on Form 20-F of Sanofi, which was filed with the SEC. Sanofi makes no commitment to update forward-looking information and statements subject to applicable regulations, in particular articles 223-1 et seq. of the general regulations of the Financial Markets Authority.
Attachment